Real-World Evaluation Of Ducressa-Based Postoperative Regimens After Cataract Phacoemulsification With Intraocular Lens Implantation
Published 2026 - 44th Congress of the ESCRS
Reference: POCAT172 | Type: Poster | DOI: 10.82333/wjn5-gq19
Authors: Prof. Dr Neilya Aldasheva 1 , Prof. Almira Bulgakova* 2 , Dr Asel Dzhapparkhanova 3 , Dr Altynai Kairatkyzy Kairat 4
1Second Department,Kazakh Eye Research Institute,Almaty,Kazakhstan, 2Day Surgery Unit,Kazakh Eye Research Institute,Almaty,Kazakhstan, 3Private Department,Kazakh Eye Research Institute,Almaty,Kazakhstan, 4Third Department,Kazakh Eye Research Institute,Almaty,Kazakhstan
Purpose
To evaluate the efficacy and safety of Ducressa, a fixed combination of levofloxacin and dexamethasone, in routine postoperative management after uncomplicated cataract phacoemulsification with intraocular lens (IOL) implantation, using two short-term treatment regimens.
Setting
Kazakh Research Institute of Eye Diseases, Almaty, Kazakhstan. A prospective comparative outpatient study conducted between September 2024 and June 2025.
Methods
Sixty patients (60 eyes) undergoing uncomplicated cataract phacoemulsification with IOL implantation were randomly assigned to one of two postoperative treatment regimens. One group received Ducressa four times daily for 14 days, while the second group received Ducressa for 7 days followed by dexamethasone 0.1% four times daily for an additional 7 days. Clinical assessments were performed on postoperative days 3, 7, 14, 21, and at 1 month. Outcome measures included conjunctival injection, anterior chamber aqueous clarity, ocular pain and discomfort, Total Ocular Symptom Score (TOSS; itching/burning, tearing), and the occurrence of postoperative infectious complications, including endophthalmitis.
Results
Both postoperative regimens were well tolerated and demonstrated effective control of inflammatory signs during the follow-up period. Improvement across all assessed clinical parameters was observed within the first postoperative weeks. No cases of allergic reactions, toxic effects, bacterial infection, or endophthalmitis were recorded. Early postoperative conjunctival hyperemia and mild ocular symptoms were transient and resolved without sequelae. Anterior chamber aqueous remained clear in all patients throughout the observation period.
Conclusions
In this real-world clinical setting, Ducressa-based postoperative regimens demonstrated a favorable efficacy and safety profile following uncomplicated cataract phacoemulsification with IOL implantation. Both treatment approaches were associated with comparable clinical outcomes and good tolerability. These findings support the use of Ducressa as a practical option for routine postoperative management, allowing flexibility in treatment duration while maintaining effective inflammation control and infection prevention.